申请人:Catena Ruiz Juan Lorenzo
公开号:US20120071466A1
公开(公告)日:2012-03-22
The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type I (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration.
公式(I)的化合物是从过氢化喹啉和过氢化异喹啉衍生而来的,可用作预防或治疗由11-β-羟基类固醇脱氢酶I(11-β-HSD1)酶相关疾病引起的活性药用成分,如青光眼、眼压升高、代谢紊乱、肥胖、代谢综合征、脂质代谢异常、高血压、糖尿病、动脉粥样硬化、库欣综合征、银屑病、类风湿性关节炎、认知障碍、阿尔茨海默病或神经退行性疾病。